Due to the characterization of the PML-RARA gene caused by t (15; 17) and its effect on leukemia development, patients with APL now benefit from a targeted therapeutic approach primarily utilizing differentiation therapy. The gene discussed is RARA; the disease is acute promyelocytic leukemia.